FlexGuard Benefits: The Three Things It Is Made to Support

Comfort is the softest of the three words and the most honest. It is not pain relief, it is not a treatment, and it carries no promise about a diagnosis.

The rows behind it are the four plant ingredients. Boswellia is the one with a direct joint literature: a 2003 crossover trial used 333 mg three times a day and reported less knee pain and greater walking distance, and a 90-day trial of a concentrated AKBA extract reported improvements at 100 mg and 250 mg a day. At 67 mg this label is in that neighbourhood.

Turmeric's joint trials, summarised in a 2016 meta-analysis, used about 1,000 mg a day of curcuminoids. Quercetin and bromelain are on the panel at 8 mg each, which is below the amounts their own studies used by a wide margin.

So the fair statement of this claim is: one of the four ingredients behind it is present at an amount its research would recognise, and three are not.

This is the glucosamine and chondroitin claim, and it is the one with the largest pile of evidence and the least agreement about what that evidence shows.

NCCIH's summary is the fairest short account: some studies find benefit, the better-conducted ones tend to find less, and the results vary by preparation. The 2019 American College of Rheumatology guideline recommends against glucosamine for knee, hip and hand osteoarthritis, and the 2019 OARSI guidelines decline to endorse it for symptom relief either.

Both of those conclusions are about a diagnosed condition, at 1,500 mg a day. Neither is a conclusion about a 500 mg comfort claim in somebody who has no diagnosis, which is a different question nobody has run a trial on.

The honest version, then: the ingredient with the largest evidence base in this category has a disputed record at three times this amount, and this website prints that rather than quoting only the encouraging half.

The broadest of the three and the hardest to test, because everyday joint stress is not a measurable endpoint in anybody's trial.

What it describes is real enough: standing on a hard floor for a shift, kneeling to lay a floor, carrying shopping up two flights, a long drive. The rows behind it are MSM, bromelain and quercetin, which are the three smallest on the panel.

A claim this broad is where a supplement page usually reaches for language it cannot support. The version this desk will stand behind is narrow: the capsule supplies small amounts of ingredients studied in that general area, at amounts below those studies, once a day.

The Arthritis Foundation's own supplement guide is a useful outside reading of the same ingredient list, written by an organisation with nothing to sell in this transaction.

It does not treat, cure, prevent or manage arthritis, osteoarthritis, rheumatoid arthritis, gout or any other named condition. It does not rebuild cartilage, it does not reverse anything, and it is not a substitute for a prescription.

Those sentences are not legal decoration. The FTC’s health products compliance guidance sets out what a supplement seller must be able to substantiate before saying it, and a claim of that kind on a product with no trial of its own could not be substantiated by anybody.

The practical version for a buyer: if a page about a joint supplement uses the word treats, close it. The claims ceiling is not a formality and the products that respect it are the ones telling you the truth about everything else.